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should involve an assessment of this interaction, which can only 
partially be simulated with phantoms. The dynamic and even more 
importantly the automatic real-time adaptive nature of the tumor 
tracking process add some additional requirements to the QA process. 
Acquisition of intrafraction imaging in combination with logging of 
dynamic machine parameters during treatment allow a detailed 
quantification of the tracking performance at all times during 
treatment delivery. An overview is given of the RTTT process with the 
Vero gimbaled linac system in clinical practice. 
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There is an increasing participation, involvement and visibility of 
young members in ESTRO over the last years with the development of 
pedagogical and research activities, structures and tools targeted to 
young members and often conducted by young members but open to 
all ESTRO members.  
In 2007 a young scientific committee was created to orgasine a young 
ESTRO track for ESTRO27 meeting in Göteborg. Since then young 
ESTRO session (for all four disciplines in radiation oncology) has been 
part of each ESTRO annual meeting and each ESTRO forum expending 
to a full day track since the London ESTRO aniversary meeting in 2011. 
In late 2009 the young corner in the ESTRO newsletter was created to 
provide an additional communication tool between society members 
and more specifically between young members. Since 2010 each 
standing committee has at least one young representative who is 
considered as a liaison person between his committee and young 
members (through the young scientific committee and/or the editorial 
team of the young corner). 
The first young task force was created following the young session at 
the ESTRO aniversary meeting. This task force has proposed a 
roadmap for the development of young members integration in the 
society approved and signed by the president of ESTRO and the chair 
of this young task force at ESTRO31 in 2012 [1]. This roadmap states 5 
key points: setup a young strategy meeting, develop young activities 
in ESTRO, support young professionals in their scientific activities, 
promote educacional activities, provide better access for young to 
ESTRO services. 
This comes in agreement with the ESTRO vision published after the 
2012 ESTRO strategy meeting where young representatives were 
invited as well [2]. This document recognises ”the strategic 
importance of young members to the development and future of 
ESTRO and the clinical discipline of radiation oncology” and confirms 
that the ESTRO board commits to ”prioritise initiatives to increase 
young member participation in the society”. 
One of the key points of the roadmap was already achieved through 
the young strategic meeting organised in Taormina in october 2012. 
This has lead to a list of priorities with an action plan. Further 
achievments will be delivered in the second ESTRO forum in Geneva in 
2013 together with a roadmap for the futur young task force leading 
to the signature of a new contract. 
References: 
1.http://www.estro.org/about/Documents/Young%20Task%20Force/R
oadmap_BCN_2012_final.pdf 
2. Valentini V, Bourhis J, Hollywood D. ESTRO 2012 strategy 
meeting: vision forradiation oncology. 
RadiotherOncol. 2012Apr;103(1):99-102 
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The first young task force was formed at the Anniversary meeting in 
London in 2011 under the impulsion of President Jean Bourhis and 
President elect Vincenzo Valentini. The aim was to settle a group of 
young persons involved in ESTRO or recruited outside of ESTRO to 
implement concrete advances for young people. The ESTRO President 
chairs the task force and the task force is partly renewed every year. 
Its first mission was to conduct a survey to better understand the 
needs of young members from all over Europe. This task force 
finalized its work at the ESTRO 31 in Barcelona with the signing of a 
roadmap, an agreement between young ESTRO members and ESTRO 
president showing the deep commitment of ESTRO board towards the 
expectations of young people in the field of radiation oncology and 
the road to follow in the near future. 
The new task force has had the objective to transform the roadmap 
into actions leading to a contract that will be signed at the 2nd ESTRO 
Forum in Geneva in 2013. One of the first points ofthe roadmap was to 
conduct a strategy meeting for young people, in order to discuss key 
challenges in the field of radiation oncology. This retreat took place in 
Taormina, Sicily, in October 2012 and was the occasion of fruitful 
exchanges between young people (physicists, radiation 
oncologists,radiobiologists and RTTs) from all over Europe and 
distinguished members of the ESTRO board, including the three 
Presidents, the Green Journal’s editor in chief and the chairman of 
the Education committee. Major topics included educational services, 
scientific exchange, professional/membership issues and young 
member’s society structures. It ended with a session devoted to the 
implementationof new activities for young members. 
The young ESTRO task force is now facing great and exciting 
challenges. Bringing up new ideas is good, but helping and making 
them become true is even better. Improving education, clinical or 
scientific exchange, networking or web-based services are some of the 
ongoing projects where the young task force is involved. This is the 
real goal of the previous young task forces, and of the coming ones. 
The major priorities defined by the young Task Force and the ESTRO 
board will be presented during the session. 
If you are interested, come to the session, and you will see what 
ESTRO can do for young people, but also how young people can help 
improving ESTRO services. 
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This session marks the finalization of the 2nd Young Task Force (YTF), 
a concept created following prolific discussions during and following 
the ESTRO 30 year anniversary conference in 2011. The YTF is an 
instrument designed for a dynamic and efficient interaction between 
the core management structures of ESTRO and the youngest members 
of the society.  This is achieved by appointing the members of the YTF 
on an annual basis, with a mission to work along a roadmap defined by 
the previous task force.   
The current YTF has focused on identifying and exploring the different 
needs and aspirations of young RT scientists / ESTRO members within 
the different domains of ESTROs core activities. At the time of 
writing, the different ideas put forward are being evaluated, and the 
details of this will form the backbone of the mission for the next YTF. 
Overall, the new activities proposed for the next YTF will complement 
the existing activities for and by young ESTRO members (e.g., 
conference activities, newsletter and general information activities) 
and will also be seen as an integral part of the general development 
of the society. During this session the final details of this process will 
be described and the roadmap for the next YTF will be signed by the 
president of the society.   
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Purpose/Objective: Second primary cancers (SPC) are among the 
possible late toxicities in Hodgkin’s lymphoma (HL) survivors. The 
extent of radiation fields and high doses are counted among probable 
aetiological causes. We reviewed long term results of a mono-
institutional, randomized trial comparing sub-total nodal irradiation 
(STNI) versus involved-field irradiation (IFRT) after a short-course of 
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chemotherapy to evaluate the rate of second cancers and their sites 
according to the extension of radiation fields. 
Materials and Methods: From 1990 to 1995, 140 patients (pts) with 
early-stage HL (IA, IB, IIA ± bulky) received 4 cycles of ABVD and then 
they were randomized to receive STNI (36 Gy to involved sites and 30 
Gy to uninvolved sites) or IF (36 Gy to involved sites). The endpoints 
of this review were to assess the rate of late toxicity in term of SPC 
and the spatial relationship between radiation fields extent and SPC. 
We used the topographical criteria defined by Dorr1 to localize SPC 
compared to RT fields. Event-free survival (EFS) and overall survival 
(OS) were estimated by Kaplan-Meier method. Crude and age-adjusted 
incidence rates of SPC were calculated by Poisson regression.  
Results: After a median follow-up of 203 months, 24 SPC were 
observed: 7 cutaneous basal cell carcinomas, 1 MDS, 16 solid tumours 
(11 breast, 2 prostate, 1 ovary, 1 skin, 1 colon). For this study we 
evaluated only solid cancers.  13 SPC were in STNI arm, 3 in IFRT (p 
0.014). Median time to second malignancies was 172 months in STNI 
and 178 in IFRT. IR (incidence rate/1000 person-years) 12.9 in STNI 
and 2.76 in IFRT (p 0.014). In a univariate analysis, the second 
malignancies risk is higher in STNI versus IFRT (hazard ratio 4.40, 95% 
CI). According to the topographic criteria, SPC were located as listed 
below: 
 
 In-field Margin Adjacent Distant
Breast 8 3 0 0 
Other 0 0 2 3 
 
Dose at in-field region was 36 Gy in all cases. 
Median age at breast cancer diagnosis was 43years (27y at HL 
diagnosis); median age at diagnosis of other cancers was 62y (49y at 
HL diagnosis). 7 breast cancers (5 infiltrating carcinoma and 2 in situ) 
were treated with conservative surgery and in 5 cases radiation-
therapy was performed. 2 breast cancer pts died (1 myocardial 
infarction, 1 disease progression). All the remaining pts are alive and 
with no evidence of both tumours. 
Conclusions: Combined modality treatment is currently the treatment 
of choice for early-stage HL. In this setting of patients, RT contributes 
to achieving a high cure-rate. Despite the fact that the optimal size of 
RT fields and dose are still unknown, our data confirm that reducing 
of field size to IF is safe both in terms of cure rate and reduction of 
second cancers. 
1) Dörr W, Herrmann T Second primary tumors after radiotherapy for 
malignancies. Treatment related parameters. Strahlenther Onkol 
2002; 178: 357-62 
 
PD-0527  
Impact of CD63-positive inflammatory cells on the survival of 
glioblastoma multiforme patients 
J. Jaal1, M. Kase2, A. Adamson2, M. Saretok2, A. Minajeva2, M. Vardja1, 
T. Asser3 
1Tartu University Hospital, Dept of Radiotherapy and Oncological 
Therapy, Tartu, Estonia  
2University of Tartu, Faculty of Medicine, Tartu, Estonia  
3Tartu University Hospital, Dept of Neurosurgery, Tartu, Estonia  
 
Purpose/Objective: Glioblastoma multiforme (GBM) is the most 
aggressive type of brain cancer in adults. It is suggested that tumour 
microenvironment might influence treatment outcome of cancer 
patients. The aim of this study was to evaluate the impact of 
inflammation on treatment response and survival of GBM patients. 
Materials and Methods: Between Jan 2006 and Dec 2008, 42 patients 
were operated and received postoperative radiotherapy 
(±chemotherapy). Surgically excised GBM tissues were immuno-
histochemically examined for CD63 expression. Since CD63 is 
expressed on inflammatory cells (monocytes, macrophages, 
granulocytes), the number of CD63-positive (CD63+) cells per 
microscopic field was determined. Also, haematoxylin-eosin stained 
tumour sections were histologically examined for overall proportion of 
necrosis (%) and microvascular proliferations (MP; low, medium, high). 
Finally, CD63 expression was correlated with patients overall survival. 
Results: Immunohistochemical parameters were examined by 2 
independent researchers whose results were in good accordance 
(R=0.8, p<0.0001). The number of CD63+ inflammatory cells per 
microscopic field was 62.1±23.1 (mean±SD). A significant association 
was found between the number of CD63+ cells and the proportion of 
necrosis (p=0.004). Also, a correlation between the number of CD63+ 
cells and the proportion of MP was detected (p=0.009). Median 
survival time of the study group was 10.0 months (95% CI 9.0-11.0). 
However, the survival time clearly depended on the number of CD63+ 
cells in GBM tissue (log rank test, p=0.003). Median survival times for 
patients with low (less than median) and high (equal or more than 
median) number of CD63+ cells were 9.0 months (95% CI 8.1-9.9) and 
12.0 months (95% CI 8.5-15.5) respectively. In multivariate analysis, 
the number of CD63+ cells emerged as a significant independent 
predictor for longer overall survival (HR 2.4, 95% CI 1.2-5.1, p=0.02). 
Conclusions: Present study revealed a beneficial role of inflammation 
on survival of GBM patients. In patients with higher number of CD63+ 
cells prior radiotherapy, significantly longer survival times were 
achieved. Additionally, inflammatory reaction was associated with 
tumour micromilieu: there were more inflammatory cells in the 
presence of high proportion of necrosis and MP. Clearly, more studies 
are needed to evaluate the role of inflammation and tumour 
microenvironment on GBM treatment outcome. 
This work was supported by Institutional Research Funding 
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Purpose/Objective: Re-irradiation has been shown to be an option for 
recurrent high-grade glioma patients with proven but limited efficacy. 
Furthermore, bevacizumab exerts certain efficacy in combination with 
chemotherapy or as monotherapy and was safely tested in 
combination with radiotherapy for re-treatment in smaller studies. 
This report gives an update on the outcome of patients treated at the 
University hospital of Munich. To our knowledge, this is the largest 
cohort including patients treated with both re-irradiation and 
bevacizumab to date. 
Materials and Methods: After receiving standard radiotherapy (with or 
without TMZ) patients with recurrent malignant glioma were treated 
with bevacizumab (10mg/kg intravenously at d1 and d15) during re-
irradiation. Median prescribed radiation dose during re-treatment was 
36Gy, conventionally fractionated. 
Results: 71 patients re-irradiated in a single institution were 
retrospectively analyzed. Patients either received bevacizumab 
(N=57), other substances (N=4) or radiation alone (N=10). Re-
irradiation was tolerated well regardless of the additional therapy. In 
one patient with bevacizumab a wound dehiscence occurred, one 
patient suffered from deep vein thrombosis resulting in pulmonary 
embolism. One patient died of a perforated sigma diverticulitis. Post-
recurrence survival was significantly increased in patients receiving 
bevacizumab (p=0.003, log-rank test) as well as progression-free 
survival (p=0.005, log-rank test). KPS, surgery, MGMT, sex, WHO grade 
and age showed no statistically significant improvement in neither PFS 
nor survival. 
Conclusions: Re-irradiation with bevacizumab remains a feasible and 
highly effective treatment schedule. Studies on further salvage 
strategies and timing of sequential treatment options vs. observation 
are warranted.  
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Purpose/Objective: In order to define new prognostic subgroups in 
patients with glioblastoma (GBM) a method is presented how to derive 
potentially prognostic miRNA patterns employing a large screen (> 
1,200 miRNAs) from paraffin tissues including associated 
methodological problems and pitfalls. 
Materials and Methods: Thirty-six GBM patients treated in a single 
institution basically according to the EORTC/NCIC protocol between 
1/2009 - 12/2010 were included in this retrospective analysis. For 
microarray analysis, the febit biochip 'Geniom® Biochip MPEA homo 
sapiens' was used. Total RNA was isolated from FFPE slides, altogether 
over 1,200 different miRNAs were analyzed. In order to define 
significant patterns, a Cox regression analysis for each single miRNA 
was performed using long-term survival (split at 450 days) as censor; 
significant miRNAs (without multiple-testing correction) were chosen 
and a hierarchical clustering analysis was performed; survival of the 
